Ongoing, prospective multicenter safety study of subcutaneous amifostine for non-small cell lung cancer (NSCLC)

Autor:	K. R. Fullmer, R. C. Nichols
Rok vydání:	2005
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment non-small cell lung cancer (NSCLC) Amifostine medicine.disease Radiation therapy Internal medicine medicine business medicine.drug Mucosal tissue
Zdroj:	Journal of Clinical Oncology. 23:7251-7251
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.7251
Popis:	7251 Background: Amifostine (Ethyol) is a radioprotectant that protects mucosal tissue from chemotherapy- and radiotherapy (RT)-induced damage. Intravenous administration is the approved route, but...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5bba38f4b7d597e2ec3b125e75521edc https://doi.org/10.1200/jco.2005.23.16_suppl.7251 Zobrazit plný text záznamu